Alaunos Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 1
- Market Cap
- $4.4M
- Website
- http://www.alaunos.com
- Introduction
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The compa...
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 548
- Registration Number
- NCT01555710
- Locations
- 🇺🇸
Medical Oncology Associates Of Wyoming Valley, PC, Kingston, Pennsylvania, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Swedish Medical Center, Seattle, Washington, United States
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT01397708
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸The Angeles Clinic, Los Angeles, California, United States
Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT01340547
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT01242072
- Locations
- 🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Medical Consultants, PC, Muncie, Indiana, United States
🇺🇸Washington University, St. Louis, Missouri, United States
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 447
- Registration Number
- NCT01168791
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Registration Number
- NCT01139359
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT01139346
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT01113970
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇺🇸Evergreen Hematology Oncology, Spokane, Washington, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
- Conditions
- First Posted Date
- 2008-12-30
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT00815607
- Locations
- 🇺🇸
Goshen Clinic, Goshen, Indiana, United States
🇺🇸Billings Clinic, Billings, Montana, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 7
- Registration Number
- NCT00726687